Drug Profile
Research programme: bacteriophage therapies - Pherecydes
Alternative Names: P. aeruginosa phage therapy - PHAXIAM Therapeutics; PP 1231; PP 2351; S. aureus phage therapy - PHAXIAM TherapeuticsLatest Information Update: 25 Sep 2023
Price :
$50
*
At a glance
- Originator Pherecydes Pharma
- Developer PHAXIAM Therapeutics
- Class Bacteriophages; Pseudomonas phages; Staphylococcus phages
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bacterial endocarditis; Klebsiella infections; Urinary tract infections
- No development reported Bone and joint infections; Respiratory tract infections